Peter MacCallum Cancer Centre, Australia: Phase 1 study withdrawn (Metastatic Castrate Resistant Prostate Cancer (mCRPC))
Peter MacCallum Cancer Centre, Australia: Phase 1 study withdrawn (Metastatic Castrate Resistant Prostate Cancer (mCRPC)). Dated 6 days ago, it is inside the fresh trigger window. Score 50/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Sponsor type | Academic and hospital |
| Study | Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer |
| NCT ID | NCT07090369 |
| Phase | Phase 1 |
| Status | withdrawn |
| Conditions | Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| Intervention types | drug, radiation |
| Site countries | Australia |
| Posted | 2025-07-29 |
| Planned start | 2025-11-01 |
| Event | Withdrawn before enrolling |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Peter MacCallum Cancer Centre, Australia
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Peter MacCallum Cancer Centre, Australia + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Peter MacCallum Cancer Centre, Australia and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
50 / 100 Score
- Posted in the last two weeks.
- Stopped early: budget and sites freed up.
What is the ClinicalTrialStartPulse record for Peter MacCallum Cancer Centre, Australia?
Peter MacCallum Cancer Centre, Australia's Phase 1 study (NCT07090369) in Metastatic Castrate Resistant Prostate Cancer (mCRPC), first posted 2025-07-29: withdrawn before enrolling (2026-10-30), in an update posted 2026-10-30.
How does Peter MacCallum Cancer Centre, Australia compare to other ClinicalTrialStartPulse records?
It is fresh: dated 6 days ago, inside the window where early outreach matters most.
Peter MacCallum Cancer Centre, Australia vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Peter MacCallum Cancer Centre, Australia | NONUS | 2026-10-30 | ||
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Peter MacCallum Cancer Centre, Australia and peer phase 1 records
Get new ClinicalTrialStartPulse records like Peter MacCallum Cancer Centre, Australia by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.